Lv1
60 积分 2025-08-21 加入
Circulating tumor DNA-minimal residual disease: An up-and-coming nova in resectable non-small-cell lung cancer
21小时前
已完结
Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer – Decision criteria in routine practise
2天前
已完结
167 CONCORDE: A Multicentre Phase Ib Trial of DNA Damage Response Inhibitors and Durvalumab Consolidation in Patients with Unresectable Stage IIB/III NSCLC Undergoing Radiotherapy: The Newcastle experience
16天前
已完结
皖公网安备34019202002308
